Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vivani Medical ( (VANI) ) has provided an update.
On January 25, 2026, Vivani Medical, Inc. priced a best-efforts registered direct offering of 1,689,200 common shares at $1.48 per share and a concurrent private placement of 1,351,351 common shares at the same price to an entity affiliated with board chairman Gregg Williams, for expected combined gross proceeds of approximately $4.5 million before fees and expenses. The private placement, conducted without warrants, discounts or placement fees, and the registered offering, arranged through ThinkEquity as sole placement agent with customary lock-up agreements for directors and officers, are expected to close on or about January 27, 2026, and will provide additional capital for ongoing research and clinical development of Vivani’s drug implant candidates, as well as working capital and general corporate purposes, modestly strengthening the company’s balance sheet and funding runway for its metabolic disease pipeline.
The most recent analyst rating on (VANI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Vivani Medical stock, see the VANI Stock Forecast page.
Spark’s Take on VANI Stock
According to Spark, TipRanks’ AI Analyst, VANI is a Neutral.
The score is primarily held back by weak financial performance (pre-revenue, large losses and cash burn) and elevated balance-sheet risk from high leverage. Technicals also point to a downtrend despite oversold signals. Offsetting these negatives, recent corporate developments and funding provide near-term support and potential clinical catalysts.
To see Spark’s full report on VANI stock, click here.
More about Vivani Medical
Vivani Medical, Inc. (Nasdaq: VANI) is a clinical-stage biopharmaceutical company that leverages its proprietary NanoPortal platform to develop miniature, ultra long-acting drug implants designed to deliver medications steadily over extended periods. The company is focused on GLP-1-based implants targeting metabolic diseases such as obesity and type 2 diabetes, aiming to address widespread medication non-adherence and improve patient tolerance compared with traditional daily or weekly oral and injectable therapies.
Average Trading Volume: 298,323
Technical Sentiment Signal: Hold
Current Market Cap: $100.7M
See more data about VANI stock on TipRanks’ Stock Analysis page.